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ABSTRACT 
Objective: The present study was aimed to develop and evaluate quantum dots (QDs) as a carrier for delivery of 5-fluorouracil (5-FU).  
Methods: This research work includes a synthesis, characterization and in vitro study of 5-fluorouracil (5-FU) QDs. Zinc oxide QDs were 
synthesized, and the drug was loaded on them. These QDs were further coated with Eudragit E PO to achieve drug release only at the acidic pH 
range as well as to overcome release of drug in the formulation vehicle itself.  
Results: For 5-FU QDs optimized batch, yield (74±0.001 %), drug loading (85.58±0.08 %) and drug content (95±0.015%) were observed. FTIR 
spectroscopy revealed no any incompatibility between drug, polymer and metal SEM images shown drug loaded QDs with rough surface and 
Eudragit E PO coated QDs with smooth surface. The DSC curve of 5-FU exhibits peak at 286 °C corresponding to its melting point and Eudragit E PO 
coated QDs exhibit peak at 272 °C. This shifting of the endotherm suggested possible interaction of 5-FU and Eudragit E PO coated QDs. The 
diffractogram of pure drug showed multi-crystalline nature. However pure Eudragit E PO showed amorphous nature. Optimized QDs showed the 
crystalline nature of the drug. Mean particle size of optimized formulation batch was 201.92 nm and zeta potential was found+1.85 mV.  
Conclusion: An Optimized batch of QDs has the potential to utilize in future for imaging of cancer cells and targeting delivery of 5-FU. 
Keywords: Anti-cancer, 5-fluorouracil, Nanoparticles, Quantum dots, Targeted drug delivery. 
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INTRODUCTION 
Quantum dots (QDs) are very tiny particles of about a nanometer in 
size. QDs consist of a semiconductor material with a diameter in the 
range of 2-10 nanometers. The color of Quantum dots depends on 
the size of the dot or particle. Quantum dots are a novel class of 
inorganic fluorophore, which are gaining widespread recognition 
due to their exceptional photophysical properties. Due to 
fluorescence property in them, when the light is emitted for them of 
a certain wavelength, it shows fluorescence light at targeted sites. 
This application of QDs is being used in imaging of the cells in the 
body, when these QDs are coated with the specific category of drug. 
These quantum dots possess a metal on which the drug is coated [1]. 
Quantum dots are emerging as a new class of fluorescent probes for 
biomolecular and cellular imaging. The nature of this technology 
makes it suitable for application such as in vivo imaging, including 
live cell and whole animal imaging, blood cancer assay, cancer 
detection and treatment [2]. 
A general QD comprises of three main parts. At the center of the 
structure, there is a single core having a diameter in nanometers, 
whose size and shape can be changed. Around this, the core is coated 
with the QD shell possessing the optical properties, as this shell 
contains the semiconductor metal. QD shell is then coated with the 
outer layer depending upon the application for which QDs are to be 
used [3]. 
The ability of quantum dots to glow fluorescence after reaching the 
target site can be used in a targeted drug delivery. As quantum dots 
coated with drug reaches the target site it causes the interaction 
between the surface charge of target cells and the charge of material. 
Due to such application of quantum dot it is used here as a carrier 
for an administration of the anticancer drug.  
The small size of quantum dots allows them to go anywhere in the 
body, making them suitable for different biomedical applications like 
medical imaging, biosensors, etc. Photostability is one of the greatest 
advantages of QDs for in vivo applications since it allows images to be 
recorded over a longer period of time than available with the use of 
fluorescent dyes or proteins, due to resistance in photobleaching [4]. 
Many tumor types can be identified purely based on their image 
contrast [5]. Recent studies using quantum dots in neuroscience 
illustrate the potential of this technology. Antibody-functionalized 
quantum dots are used to track the lateral diffusion of glycine 
receptors in cultures of primary spinal cord neurons [6]. The drug 
used to coat QDs is 5-fluorouracil (5-FU), which is an anticancer drug 
that helps in treating most of the cancers of head, neck, breast, etc. Till 
date, solid lipid nanoparticles and polymeric nanoparticles had been 
prepared by using 5-fluorouracil. However, QDs of 5-fluorouracil have 
not been reported yet, so there was scope to formulate QDs. 
MATERIALS AND METHODS 
Materials 
5-fluorouracil, an active pharmaceutical ingredient was obtained from 
Yarrow Chem Products, Mumbai, India. Eudragit E PO, used as polymer 
was obtained from Sava Pharmaceuticals, Pune, India. Methanol, nitric 
acid, chloroform, sodium hydroxide, potassium dihydrogen phosphate, 
disodium hydrogen phosphate were of analytical grade.  
Methods 
Calibration of 5-FU by using UV Spectrophotometer (Florey 
2005) 
First the wavelength of 5-fluorouracil by using methanol as a solvent was 
determined as depicted in (fig. 1). The calibration was carried out in 
methanol due to the higher solubility of the drug in it as shown in (fig. 2). 
Further, at obtained wavelength the calibration was carried out by 
preparing the samples of different concentrations (ppm). The samples 
were diluted if necessary. Later on, absorbance was measured, and it 
was seen that the range obeys the beer’s and Lambert’s law. 
Preparation of zinc oxide (ZnO) quantum dots 
According to this procedure, zinc chloride was dissolved in nitric acid 
(HNO3) and to this mixture methanol was added and it was dried at a 
suitable temperature. Now this dried sample was dissolved in methanol. 
Sodium hydroxide, which was dissolved in methanol, was added in after 
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some time to zinc nitrate solution with vigorous stirring. The 
temperature was maintained for a specific period of time, and then the 
solution becomes translucent. After this time period, the quantum dots 
start to precipitate, and the solution becomes turbid. The heating and 
stirring of the sample were stopped and later on the precipitation of 
these nano particles was continued for an additional period of time. The 
precipitate was obtained, and the mother liquor was separated, and then 
the precipitate was washed with methanol as depicted in (table 1) [7]. 
Drug loading on ZnO quantum dots 
Initially, QDs were dispersed in methanol. 5-FU was added to that 
mixture and 5-FU gets dissolved as it has solubility in methanol. Cold 
water was added slowly to QDs-drug mixture. The role of cold water 
is to coat 5-FU on the QDs. 5-FU came out and loaded up on the 
uncoated QDs. This drug loaded QDs were further dried in the oven 
at 70 °C as depicted in (table 2). 
Polymer coating on drug loaded quantum dots 
Firstly, Eudragit E PO polymer was dissolved in chloroform. Further, 
drug loaded QDs were weighed and then dispersed in the polymer 
solution. This mixture was kept in undisturbed condition for 15 min 
and then stirred. Later on, this mixture was filtered using Whatman 
filter paper. Finally, polymer-coated QDs were air dried for 
overnight as depicted in (table 3). 
  
Preparation of batches of uncoated QDs  
Table 1: Batches of uncoated QDs 
Batch  Source of metal used Quantity used Quantity of nitric acid (0.1N) used Quantity of methanol (99% v/v) used 
B 1 ZnCl2 0.0985 g 0.29 ml 5 ml 
B 2 ZnCl2 1 g 0.29 ml 5 ml 
B 3 ZnCl2 1 g 0.30 ml 5 ml 
B 4 ZnCl2 1.5 g 1 ml 10 ml 
B 5 ZnCl2 5 g 1 ml 7 ml 
 
Preparation of batches of drug loaded QDs  
Table 2: Batches of drug loaded QDs 
Batch  QD: Drug  Solvent and volume of solvent used Coating solvent 
B 1 1: 0.5  Methanol-5 ml Cold water-5 ml 
B 2 1:1 Methanol-5 ml Cold water-5 ml 
B 3 1:1  Methanol-5 ml Petroleum ether-5 ml 
B 4 1:1 Methanol-5 ml Acetone-5 ml 
B 5 1:2 Methanol-5 ml Cold water-5 ml 
 
Preparation of batches of Eudragit E PO coated QDs 
Table 3: Batches of Eudragit E PO coated QDs 
Batch Solvent and volume of solvent used Quantity of QDs taken Quantity of Eudragit E PO taken Eudragit grade used 
B 1 Chloroform-3 ml 2.5 mg 2% Eudragit E 100 
B 2 Chloroform-20 ml 10 mg 5% Eudragit E 100 
B 3 Chloroform-3 ml 2.5 mg 2% Eudragit E PO 
B 4 Chloroform-20 ml 10 mg 5% Eudragit E PO 
 
Eudragit E 100 and Eudragit E PO polymers were selected for 
coating over the drug loaded QDs. Due to unsatisfactory results of 
coating efficiency of Eudragit E 100, finally, Eudragit E PO was 
selected for loading, as it gave satisfactory results as compared to 
Eudragit E 100. Further, it was decided to incorporate Eudragit E PO 
coated QDs in chloroform as the Eudragit E PO is insoluble in it. So 
that, Eudragit E PO layer will not get dispersed into aqueous 
formulation vehicles. However, as the cancerous target tissues or 
cells have an acidic environment, Eudragit E PO is expected to get 
released in the pH range of 1-5 due to its solubility at this acidic pH 
range.  
Characterization of 5-FU QDs 
Differential scanning calorimetry (DSC) 
DSC measurements were performed on a differential scanning 
calorimeter equipped with an intra-cooler (DSC Mettler STAR SW 
9.20, Switzerland). The inert atmosphere was maintained by purging 
nitrogen gas at a flow rate of 50 ml/min. All accurately weighed 
samples (about 3-5 mg) were placed in a sealed aluminium pan, and 
the samples were heated under nitrogen gas flow (20 ml/min) at a 
scanning rate of 10 °C per min from 40 to 240º C. An empty 
aluminium pan was used as a reference. DSC analysis was performed 
for pure 5-fluorouracil as shown in (fig. 3) and Eudragit E PO coated 
QDs as shown in (fig. 4) [8]. 
X-ray diffraction studies (XRD) 
X-ray diffraction studies provide information about the crystallinity 
of the sample, which is reflected by a characteristic fingerprint 
region in the diffraction pattern. Studies were carried out by using 
ORIGIN 8 Version 8E with a resolution of 0.001A °. Vacuum grease 
was applied over the glass slide to stick the sample. About 2 mg of 
sample was sprinkled over to form a layer. The samples were 
radiated using a Cu target tube and exposed to all lines (λ-1.54056). 
Scanning angles ranged from 5 ° to 40 ° of 2θ. The current used was 
30 mA and voltage of 40 kV. X-ray diffraction studies of 5-FU as 
depicted in (fig. 5), Eudragit polymer as shown in (fig. 6) and 
Eudragit E PO coated QDs as shown in (fig. 7) were carried out 
(ORIGIN 8 Version 8E) [9]. 
Particle size and zeta potential 
The average particle size of prepared 5-FU QDs was measured by 
particle size analyzer (NANOPHOX-NX0088). 5-FU QDs were diluted 
with distilled water to make 5% v/v. The particle size distributions 
were estimated by setting the intensity of the scattered light at a 
wavelength of 750 nm and the scattering angle (θ) of 90 °. The particle 
size of Eudragit E PO coated QDs was determined as depicted in (fig. 
8). Zeta potential of Eudragit E PO coated QDs was determined by 
Beckman Coulter as shown in (fig. 9), to analyze particle size and zeta 
potential samples were diluted with ultra pure water. 
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Percentage yield, drug loading and drug content 
The QDs and the drug were taken 1:2 w/w. Further, the yield of this 
batch was determined. Then, 1 mg of sample was taken from 
obtained yield and added in 10 ml of methanol. Further, dilutions 
were prepared, and absorbance was taken, it resulted that the 
absorbance value obeys the beer’s and lambert’s law. Samples were 
measured at an absorbance of 266 nm in double beam UV 
Spectrophotometer. Final calculations were done, and percentage 
yield, drug loading and drug content were determined.  
Percentage yield (%) 
weight of drug loaded QDs
Weight of drug loaded QDs + Initial weight of polymer
X 100 
The percentage yield of Eudragit E PO coated QDs was determined 
by using above formula. The values obtained were put into the above 
formula and percentage yield was determined. 
Drug loading (%) 
Actual drug content in sample of particles
Weight of drug loaded QDs
 X 100 
The drug loading of prepared Eudragit E PO loaded QDs was 
determined by using above formula. The obtained values were put 
into a formula, and drug loading was calculated. 
Drug content (%) 
The QDs and Drug were taken in 1:2 ratios. Further, yield was 
determined. Then, 1 mg of QDs were taken from obtained yield and 
diluted in 10 ml of methanol. Further, dilutions were prepared, and 
absorbance was taken, it resulted that the absorbance value obeys 
the Beer’s and Lambert’s law. Final calculations were done, and drug 
content was determined. 
Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) was used to verify the 
uniformity of particle shape and size. SEM of 5-FU QDs was carried 
out in the solid state. The surface morphology of the samples was 
observed under a scanning electron microscope (Beckman Coulter, 
NNSEM 450) as shown in (fig. 10). The samples were mounted on 
aluminium stab by using a double-sided adhesive tape. Then it was 
placed in an ion coater unit (Model: IB-2, Hitachi, Tokyo, Japan) for 
gold coating (200 A). During gold coating process the samples were 
exposed to a vacuum of 10-50 mm. After this, an accelerating voltage 
of 15 kV and 10 kV was applied, and the image was photographed by 
Asia Pentax Camera. SEM images of drug loaded QDs and Eudragit E 
PO coated QDs were determined [9]. 
Fourier transforms infrared spectroscopy (FT-IR)  
The FT-IR of pure 5-FU was carried out to determine the functional 
groups present in it as depicted in (fig. 11) [8, 10]. The FT-IR of 
Eudragit E PO was also performed as shown in (fig. 12). The FT-IR of 
zinc chloride and Eudragit E PO was carried out to determine the 
interaction between drug and excipients as shown in (fig. 13). The 
FT-IR of drug loaded QDs were done and interpreted. The FT-IR of 
Eudragit E PO coated QDs was done and interpreted. The overlay of 
drug loaded QDs and Eudragit E PO coated QDs is shown in (fig. 14). 
In vitro drug release study 
First, the phosphate buffer of pH 4.0 was prepared by dissolving 
5.04 g of disodium hydrogen phosphate and 3.019 g of potassium 
dihydrogen phosphate in distilled water (1000 ml) and final pH was 
adjusted by addition of glacial acetic acid [11]. In vitro drug release 
was performed by putting 20 mg of Eudragit E PO coated QDs in 900 
ml phosphate buffer (pH-4.0) using USP type II (Paddle) dissolution 
apparatus (TDT 08L Basic Electrolab) under stirring at 100 RPM. 
The temperature of dissolution medium was maintained at 37±0.5 
°C. Samples were withdrawn periodically at 0 min, 5 min, 10 min up 
to 95 min and the volume was replaced immediately with fresh 
medium. Sample solutions were filtered and analyzed by measuring 
absorbance in at 266 nm. Further, (%) drug release was calculated 
as depicted in (fig. 15). 
 
Fig. 1: Spectra of 5-FU 
 
RESULTS AND DISCUSSION  
5-FU was estimated by using UV spectrophotometer. The solvent, 
methanol was selected on the basis of solubility of 5-FU in it 
compared to other solvents chloroform and distilled water tested 
earlier in preliminary studies. Therefore, in the analytical method 
development, methanol was used as a solvent. Initially, λ max of 5-
FU in methanol was determined. It was found at 266 nm. So further, 
the estimation of 5-FU was carried out at 266 nm by using UV 
spectrophotometer. The dilutions of definite concentrations were 
prepared. Samples were diluted if necessary. The absorbance of 
samples was noted. It was found that the concentration ranges 5 to 
25 μg/ml obey Beer’s and Lambert’s law. For the stated range of 
dilutions for calibration curve, absorbance was found in proportion 
with the concentrations giving the value of R20.995.  
 
 
Fig. 2: Calibration curve of 5-FU 
 
Table 4: Batches of uncoated QDs 
Batch  (%) Yield obtained 
B 1 12.00±0.15 
B 2 61.25±0.21 
B 3 0.053±0.06 
B 4 0.057±0.09 
B 5 0.049±0.04 
Sample size n=03, Values are expressed as mean±SD 
 
Preparation of uncoated QDs 
The yield of uncoated QDs was found the least (0.049 %±0.04) for 
batch B 5 and the highest (61.25 %±0.21) for batch B 2. Therefore, the 
batch B2, with maximum yield, was treated for further 
experimentation.  
As quantum dots consist of semiconductor metal, it was wise to use 
zinc as a semiconductor as the core-forming metal of the quantum 
dots due to its non-toxic nature, easy availability in the laboratory 
and in addition, it possesses antimicrobial action [7]. Zinc is also 
present as a trace element in a human body. Zinc is II-VI group 
element in periodic table having the property of fluorescence upon 
the incidence of ultraviolet rays. Therefore, this property of zinc can 
Galgatte et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 289-296 
 
292 
be utilized for imaging of anticancer drug delivered at the site 
through its suitable drug delivery form. In the preparation of QDs, 
the temperature of reaction mixture was kept not more than 60 °C 
since it was found an important process variable. The addition of 
concentrated nitric acid to zinc chloride showed reddish colour and 
further addition of methanol downs to faint. The resultant QDs were 
discrete and free flowing. After preparation of batches of uncoated 
QDs, were evaluated for percentage yield. The batch having most 
percentage yield was selected for drug coating as depicted in (table 4). 
Till date some researchers have focused on cadmium–selenium QDs 
for targeting delivery of drug and some have worked on zinc-
magnesium QDs for tumor targeting. Here, in this work very simple 
method of preparation was used to prepare zinc oxide quantum 
dots, which is feasible in the laboratory. In this work, it was an 
attempt to prepare ready to formulate QDs in the liquid dosage form 
to administer parenterally. Therefore, QDs were further coated by 
pH sensitive polymer to obtain the drug release at desired site, 
which was rarely mentioned in the earlier literature. 
  
Table 5: Batches of drug loaded QDs 
Batch  QD: drug  Solvent and volume of solvent used Coating solvent 
B 1 1: 0.5 Methanol-5 ml Cold water-5 ml 
B 2 1:1 Methanol-5 ml Cold water-5 ml 
B 3 1:1 Methanol-5 ml Petroleum ether-5 ml 
B 4 1:1 Methanol-5 ml Acetone-5 ml 
B 5 1:2 Methanol-5 ml Cold water-5 ml 
 
Table 6: Batches of Eudragit E PO coated QDs 
Batch  Time is taken for release (min) drug release (%) 
B 1 95 56±0.001 
B 2 95 68±0.007 
B 3 95 80±0.014 
B 4 95 99±0.011 
Sample size, n=03, Drug release is expressed as mean±SD 
 
Preparation of drug loaded QDs 
Few batches are having different QDs: Drug ratios were prepared 
and evaluated for their drug loading, drug content and drug release 
as depicted in (table 5). Among the batches B1 to B5, the ratio 1:1 
(QDs: Drug) was found the best. The batch, with higher drug loading, 
drug content and drug release was selected. Though the solvents 
used to load the drug were used in the same quantity that is 5 ml, the 
drug loading was found better by using cold water compared to 
petroleum ether and acetone. 
Preparation of Eudragit E PO coated QDs 
Eudragit E 100 and Eudragit E PO were the polymers selected for 
coating over the drug loaded QDs. Due to unsatisfactory results of 
coating efficiency of Eudragit E 100, finally, Eudragit E PO was 
selected for coating. The purpose of Edragit coating was to make 
QDs more convenient for drug delivery by improving physical 
properties. Further, it was decided to incorporate drug loaded QDs 
in chloroform due to the solubility of Eudragit E PO in chloroform 
and due to evaporation of chloroform it was possible to coat drug 
loaded QDs by Eudragit E PO. Chloroform was the solvent kept 
common for all the batches as the drug was insoluble in it.  
The QDs at this stage were white in colour and needed more time to 
dry. The ratios of drug loaded QDs and Eudragit E PO concentration 
were varied. The batch, which showed maximum drug release was 
considered the best (table 6). 
Differential scanning calorimetry (DSC) 
DSC is considered as a tool to investigate the melting behaviour of 
crystalline materials. DSC of 5-fluorouracil and Eudragit E PO 
coated QDs were performed. The DSC curve of 5-FU exhibited the 
corresponding peak at 286 °C corresponding to its melting point. 
Eudragit E PO coated QDs exhibited a peak at temperature 272 °C. 
This shifting of the endotherm suggested a possible interaction of 
5-FU and Eudragit E PO coated QDs. This justifies that polymer has 
been loaded upon the drug loaded QDs. To achieve stability, 
compatibility between the drug and the polymer must be ensured 
which can be confirmed by the DSC and further by XRD studies. 
X-ray diffraction studies (XRD) 
An XRD peak mainly depends on the crystal size as they indicate the 
crystalline nature at a particular value at 2Ө range. In this study, 
pure 5-fluorouracil has shown a sharp peak indicating its multi-
crystalline nature. Eudragit E PO diffractograms showed peaks 
indicating its amorphous nature. The diffractogram of Eudragit E PO 
coated QDs also showed the crystalline nature. The diffractogram of 
Eudragit E PO was found different from the Eudragit E PO coated 
QDs, as it was noticed that amorphous nature of polymer was 
changed into crystalline nature in Eudragit E PO coated QDs. 
  
 
Fig. 3: DSC graph of 5-FU 
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Fig. 4: DSC graph of Eudragit E PO coated QDs 
 
 
Fig. 5: XRD of 5-FU 
 
 
Fig. 6: XRD of Eudragit E PO 
 
 
Fig. 7: XRD of Eudragit E PO coated QDs 
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Fig. 8: Particle size results of Eudragit E PO coated QDs 
 
 
Fig. 9: Zeta potential results of Eudragit E PO coated QDs 
 
Particle size and zeta potential 
The particle size of the formulation of 5-FU QDs (Batch B5) showed 
in the range of 151.01 nm to 222.91 nm. The mean particle size of 
the optimized formulation batch was 201.92 nm. It is visually 
observed that the particle size was found to be increased after 
coating of Eudragit E PO. The increase in particle size is in 
agreement with the QDs reported by Denim IT, Kadioglu D [7]. The 
polydispersity index was found 0.181. The prepared QDs were more 
uniform in particle size. Wider the particle size, the greater is the 
polydispersity index. This was determined three times (n =3) in 
order to ensure reproducibility to minimize the error. Zeta potential 
of the optimized batch was found at+1.85 mV and it further proves 
the stability of the prepared Eudragit E PO coated QDs, which 
justifies the rationale of preparing stable QDs, as stable QDs can be 
easily dispersed. Tummala S et al. have reported preparation and 
evaluation of enteric coated nanoparticles by extrusion 
spheronization technique for colorectal delivery [9]. However, in the 
present work, it was an attempt to prepare enteric coated QDs.  
 










B5 74±0.001 85.58±0.08 95±0.015 
Sample size, n=03; Values are expressed as mean±SD 
 
Percentage yield, drug loading and drug content  
Based on the evaluation parameters of drug content, drug loading 
and percentage yield, 5-FU QDs of ratio 1:2 were optimized. The 
drug content of the same batch was found maximum compared to 
other batches. Definite numbers of batches were prepared, and each 
batch was evaluated for drug loading. The batch is having ratio 1:2 of 
QDs: the drug was selected as this batch had maximum drug loading. 
The same batch had most of the percentage yield. So, as a result, 
these parameters were taken into consideration while selecting the 
best batch as shown in (table 7). The percentage yield, the drug 
content and drug loading were found less in batches B1 to B4 
compared to B5.  
 
 
Fig. 10: SEM of A) drug loaded QDs; B) Eudragit E PO coated QDs 
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Scanning electron microscopy (SEM) 
The surface morphology and shape of the 5-FU QDs were analyzed 
by scanning electron microscopy for optimized formulation confirms 
that 5-FU QDs are oval in shape with a smooth surface. Scanning 
electron microscopy was performed for drug loaded QDs and 
Eudragit E PO QDs of ratio 1:2 to obtain more information on the 
particle size and morphology. The photos of drug loaded QDs had 
shown that they have different morphologies as compared to 
formulated Eudragit E PO QDs. Moreover, the drug loaded QDs were 
observed with a rough surface, whereas Eudragit E PO coated QDs 
had a smooth surface. 
 
 
Fig. 11: FT-IR of 5-FU 
 
 
Fig. 12: FT-IR of Eudragit E PO 
 
 
Fig. 13: FT-IR of drug-polymer mixture 
 
 
Fig. 14: FT-IR of overlay of drug loaded QDs and Eudragit E PO 
coated QDs 
 
Fourier transform infrared spectroscopy (FT-IR) 
DSC is not the only studying tool to demonstrate an effective drug-
excipient interaction, but a non-thermal tool, FTIR can also be used. 
FTIR was performed to study the possible interactions between 5-
FU and other excipients. The FTIR spectrum of drug loaded QDs was 
also performed. The spectrum shows the typical characteristics of 
drug loaded QDs (e. g., the OH-stretching at 3067 cm−1, the 
methylene bands C–H at 2830 and 2360 cm-1, the C=O stretching 
vibrations due to carboxylic groups at 1985 cm−1, the 1671 cm−1 
band due to C-C bonds conjugated with C-O and COO− groups). FTIR 
spectra of Eudragit E PO reveals the characteristic absorption bands 
observed at: 3377.71 cm-1, the weak band of O-H stretching; 3070 
cm-1, strong band of aromatic C-H stretching; 2827 cm-1, the strong 
band of alkene C-H stretching; 1506.13 cm-1, the intermediate to 
strong band of C=C stretching of the alkene; 1348.96 cm-1, the strong 
band of C-O stretching of the phenolic group; 1156 cm-1, the strong 
band of C-C stretching. The FTIR spectrum of pure drug 5-FU is 
officially matched with the FTIR spectrum of polymer and drug 
loaded QDs. As all major peaks for the drug in the QDs mixture are 
observed, it has been concluded that there is no any kind of 
incompatibility between drug, polymer and metal [10]. 
 
 
Fig. 15: Drug release of Eudragit E PO coated QDs 
Sample size, n=03, Values are expressed as mean±SD 
 
Table 8: Drug release study 





















Sample size, n=03; Values are expressed as mean±SD 
 
Table 9: linear regression analysis of Eudragit E PO coated QDs 
Batch  Best fit model R-value K value 
B 1 Zero order 0.9902  1.0501  
B 2 Matrix 0.9335  8.3558  
B 3 Peppas 0.9753  3.5119  
B 4 Hixon Crowell 0.8209  -0.0065 
 
In vitro drug release study 
The percentage drug release from Eudragit E PO coated QDs was 
observed by using USP dissolution apparatus II in phosphate buffer 
at pH 4.0. The percentage drug release of optimized batch B5 having 
1:2 QDs-drug ratios was found maximum at time 95 min is given in 
Galgatte et al. 
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(table 8). The best fit model was found to be zero order as depicted 
in (table 9). The effective concentration of the drug must be reached to 
the site with a carrier to exert the action of the drug. As the cancerous 
target tissues or cells have an acidic environment, Eudragit E PO is 
expected to get released in the pH range of 1-5 due to its solubility at 
this acidic pH range. Intravenous route of administration for QDs is 
suitable because the drug is not expected to release at blood pH 7.4 but 
at acidic pH (pH 1-5) of cancerous cells.  
CONCLUSION 
It was possible to prepare successfully Eudragit E PO coated QDs for 
delivery of 5-FU. It was found that the optimized batch of QDs has 
potential so that it can be utilized in future for imaging of cancer 
cells and targeting delivery of 5-FU.  
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